Sotera Health Company Common Stock
Here’s whether Sotera Health Company Common Stock (SHC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); RSI 47 — healthy momentum range; strong 1-year return of +28.1%. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-2.18% over 10 days); 3-month momentum negative (-15.3%). Currently 21.9% off its 52-week high. Score: -1/7.
SHC is trading below its 200-day MA ($15.92) — a key warning sign the longer-term trend is under pressure. An RSI of 46.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +28.1% compares to +24.4% for SPY (beat the market by 3.7%). The current 21.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.